Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. PODCAST with prof. dr. Arnon Kater about venetoclax monotherapy in CLL patients

2. Adding itacitinib to corticosteroids does not improve the objective response rate in the initial treatment of patients
    with acute graft-versus-host disease

3. Ixazomib maintenance significantly delays the disease progression in transplant-ineligible patients with newly
    diagnosed multiple myeloma

4. Mepolizumab is associated with a 50% reduction in the occurrence of flares in patients with uncontrolled
    hypereosinophilic syndrome

5. Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) lower risk MDS relapsed/
    refractory to erythropoiesis stimulating agents